The goal of this program is to improve management of early breast cancer (BC) with anthracyclines and anthracycline alternatives and cyclin-dependent kinase (CDK) inhibitors. After hearing and assimilating this program, the clinician will be better able to: 1. Identify optimal candidates for chemotherapy through use of genomic assay scoring. 2. Weigh benefits vs risks associated with use of anthracycline containing regimens in patients with BC. 3. Appraise evidence supporting the use of nonanthracycline containing regimens for patients with human epidermal growth factor receptor 2-positive BC. 4. Mitigate the risk for venous thromboembolism associated with abemaciclib in patients with high-risk, node-positive, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative BC. 5. Analyze the clinical benefits of adjuvant ribociclib for patients with high-risk, ER-positive, HER2-negative BC.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2024-09-26 05:00:00
- End Date: 2024-09-26 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- MOC Credit Details: ABIM - 2.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Medical Oncology